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Translational research in preterm brain injury depends upon the delineation of the human neuropathology in order that animal
models faithfully reiterate it, thereby ensuring direct relevance to the human condition. The major substrate of human preterm
brain injury is the encephalopathy of prematurity that is characterized by gray and white matter lesions reﬂecting combined
acquired insults, altered developmental trajectories, and reparative phenomena. Here we highlight the key features of human
preterm brain development and the encephalopathy of prematurity that are critical for modeling in animals. The complete
mimicry of the complex human neuropathology is diﬃcult in animal models. Many models focus upon mechanisms related to
a speciﬁc feature, for example, loss of premyelinating oligodendrocytes in the cerebral white matter. Nevertheless, animal models
that simultaneously address oligodendrocyte, neuronal, and axonal injury carry the potential to decipher shared mechanisms and
synergistic treatments to ameliorate the global consequences of the encephalopathy of prematurity.
1.Introduction
Translational research in the brain injury of premature
infants involves the delineation of basic mechanisms and
therapeutic strategies in animal models and their subsequent
transformation into human clinical trials to improve neu-
rological outcome. Yet, from the outset, advances in our
understanding of preterm brain injury are directly con-
tingent upon neuropathologic studies in humans. Indeed,
translational research depends upon the initial delineation
of the basic neuropathology in the human brain and then
development of animal models that faithfully reiterate this
pathology, thereby ensuring direct relevance to the human
condition. The major neuropathologic substrate of human
preterm brain injury is the encephalopathy of prematu-
rity (EP), a term coined to characterize the multifaceted
gray and white matter lesions in the preterm brain that
reﬂect acquired insults, altered developmental trajectories,
and reparative phenomena in various combinations [1–
4]. The encephalopathy of prematurity also is associated
with hemorrhages, notably in the germinal matrix of
the ganglionic eminence and cerebellum and with focal
m i c r oo rm a c r o i n f a r c t s[ 5–7]. Because EP occurs at a time
of rapid brain growth, the insult may impact a host of
developmental programs, resulting in maturational defects
that compound the acquired lesion, for example, hypoxic-
ischemic injury leading to loss of pre-OLs in turn leading
to impaired myelination. The cause of EP is multifactorial,
and includes cerebral hypoxia ischemia and systemic infec-
tion/inﬂammation that results in glutamate, free radical,
and/or cytokine toxicity to pre-OLs, axons, and neurons
[8]. In addition, other maturation-dependent biochemical
derangements likely contribute to EP caused by the multiple
extrauterine insutls that the preterm infant experiences and
is not developmentally equipped to defend against [3]. One
example is bilirubin toxicity that may contribute to the
(nonspeciﬁc) neuronal loss and gliosis seen in the basal
ganglia in EP [3, 7, 9]. Given the heterogeneity and diverse
combinations of the lesions that comprise EP, it is not
surprising that the spectrum of neurodevelopmental abnor-
malities in preterm survivors is wide and includes, often in
combination, deﬁcits in executive functions [10, 11], autistic2 Neurology Research International
Table 1: Key developmental events in the cerebral white matter,
cortex, and subplate region in the last half of human gestation for
considering in the design of animal models of the encephalopathy
of prematurity.
(1) Cerebral white matter
(a) Development of vasculature and autoregulation
(b) Dominance of pre-OLs
(c) Overexpression of pre-OLs of calcium-permeable,
GluR2-deﬁcient AMPA receptors
(d) Expression of pre-OLs of NDMA receptors
(e) Transient expression of glutamate transporter EAAT2
(f) Transient abundance of microglia
(g) Oligodendrocyte expression of cytokine (interferon-γ)
receptors
(h) Radial glial ﬁber transformation and disappearance
(i) Late formation of ﬁbrous astrocytes
(j) Lag in the expression of superoxide dismutases
(k) Active axonal elongation
(2) Cerebral cortex
(a) Gyration
(b) Lamination
(c) Neuronal diﬀerentiation
(d) Late migration of GABAergic neurons
(e) Late formation of protoplasmic astrocytes following
neuronal migration
(3) Subplate region
(a) Ingrowth of axons and “waiting period”
(b) Involution
behaviors [12], cerebral palsy [13], and visual cognitive
impairments [14].
The goal of the following review is to highlight key
features of EP that we believe are critical to model in animal
paradigms. The patterns and mechanisms of injury in EP
are highly dependent upon the speciﬁc maturational stages
of OLs, neurons, and axons over the last half of gestation,
that is, the time frame of EP. We begin with a brief overview
of events in human preterm brain development that are
particularlyrelevanttoanimalmodeling(Table 1),giventhat
the vulnerability of pre-OLs, axons, and neurons to injury in
EP is critically dependent upon speciﬁc maturational stages.
Wethendeﬁnethemajorcomponentsoftheneuropathology
of EP that animal models need to consider (Table 2). We
conclude with a consideration of the interplay between
human and animal analyses in translational research and the
need for the two types of analysis to inform and build upon
each other towards the complete elucidation of EP and its
treatment.
2.TheDevelopmentoftheBrainintheLastHalf
of Human Gestation
The encephalopathy of prematurity spans the last half of
human gestation, a spectacular and complex period in brain
Table 2: Major histopathology features of the encephalopathy of
prematurity in the human brain.
(1) White matter
(a) Periventricular leukomalacia of the telencephalic white
matter
(i) Periventricular focal necrosis in diﬀerent stages (acute,
organizing, and macro- and/or microcysts)
(ii) Gliosis and microglial activation in the surrounding
white matter
(iii) Early loss of pre-OLs
(iv) Expression of markers of oxidative and nitrative stress
by pre-OLs
(v) Possible maturation arrest of OLs
(vi) Impaired myelin formation
(vii) Upregulation of cytokines in macrophages, activated
microglia, and reactive astrocytes
(b) Widespread axonal damage within and distant from the
necrotic foci
(c) Deﬁcit of neurons within necrotic foci, surrounding white
matter distant from the necrotic foci, and subplate region
(d) Postmitotic migrating neurons as possible reparative event
(e) Gliosis of the cerebellar white matter
(2) Gray matter
(a) Neuronal loss and/or gliosis of the cerebral cortex, thalamus,
globus pallidus, hippocampus, cerebellum, and brainstem
in diﬀerent combinations and to diﬀerent degrees, with
preferential involvement of thalamus and basal ganglia
(3) Hemorrhages
(a) Subpial
(b) Subarachnoid
(c) Germinal matrix (with suppression of cell proliferation)
(d) Cerebellum
(4) Infarcts
(a) Microinfarcts of the thalamus
(b) Focal infarcts of the cerebral cortex
growth and development. From midgestation to term, the
brain weight increases dramatically by 90%, and the cerebral
cortex changes from a smooth surface with only the Sylvain
ﬁssure to a complex pattern with all primary, secondary,
and tertiary gyri [7, 15]. The ganglionic eminence is thickest
at 20–26 gestational weeks and involutes by 34–36 weeks;
until 18 weeks, proliferating cells as identiﬁed by Ki67
immunoreactivity are present throughout the ganglionic
eminence, after which they persist ventrally until about 28
weeks and then markedly decrease [5]. Among the many
interrelated developmental events that occur during this
critical period of brain growth, several are particularly
germane to modeling EP in animals because they relate
to cellular vulnerabilities to glutamate, free radical, and
cytokine toxicities, as illustrated in the cerebral white matter
and cortex (Table 1).
2.1. Vascular Development in the Cerebral White Matter in the
Preterm Period. Immature vascular end zones irrigate distalNeurology Research International 3
ﬁelds in the preterm cerebral white matter [3, 8, 16–18], and
thus the deep and periventricular regions are susceptible to
very low basal blood ﬂow, documented in human preterm
brain by multiple techniques [8, 17, 19, 20]. This vascular
immaturity is characterized by decreased numbers of vascu-
lar perforators from the leptomeninges in the white matter
comparedtothecortex[16].Moreover,theintrinsiccapillary
plexus of the white matter has fewer and longer capillaries
and larger intercapillary spaces than that of the cortex
[16]. Functional cerebral vascular autoregulation is also
underdeveloped in the premature infant, with a propensity
for a pressure-passive cerebral circulation [8, 17, 19, 20].
Thus, the “margin of safety” for blood ﬂow of the deep and
periventricular cerebral white matter is compromised due to
its developmental anatomic and physiological features, and
these regions are vulnerable to ﬂuctuations in blood pres-
sure, as well as overt hypotension, common complications
of pulmonary immaturity, respiratory distress syndrome,
and accompanying mechanical ventilation in premature
infants.
2.2. Oligodendrocyte (OL) Development in the Cerebral White
Matter in the Preterm Period. The peak window of vulnera-
bility to PVL, that is, 24–36 weeks, coincides with the period
of dominance of pre-OLs [21, 22]. Oligodendrocyte matura-
tion from an OL progenitor into a myelinating OL involves
a sequence of developmental stages, each characterized by
a progressively complex morphology and the expression
of stage-speciﬁc markers. This progression includes the
following OL-developmental stages in increasing order of
maturation as deﬁned by cell-speciﬁc antibodies: (1) A2B5-
expressingOLprogenitors;(2)O4-expressingprecursorOLs;
(3) O1-expressing immature OLs; (4) myelin basic protein
(MBP-) expressing mature OL [21–24]. Neural stem cells
give rise to OL precursor cells around 13 gestational weeks
that proliferate and migrate throughout the brain, and then
diﬀerentiate into pre-OLs around 20 weeks [23, 24]. The O4-
positive cell comprises approximately 90% of the total OL
population in the preterm brain until about 28 gestational
weeks and accounts for at least 50% of the total population
until term [21]. In contrast, the O1-positive OL population
accounts for only about 10% of the total OL population in
the preterm infant and does not approach 50% of the total
OLpopulationatterm[21].OLspr oducingMBPﬁrstappear
around 30 gestational weeks in the cerebral white matter
[21], but active myelin sheath production, as detected by
Luxol-fast-blue which stains myelin sheath phospholipids,
does not begin until 3 postnatal months [25]. Once an axon
makes synaptic contact with its target cell, wrapping of the
axon by the myelin sheath begins, a process which depends
upon both axonal and OL maturation and multiple signaling
factors between them, many of which are yet unknown [26].
In the human cerebral white matter, OL contact with the
axon involves the extension of immature, O4+/O1+/MBP-,
“pioneer” processes that extend longitudinally along the
length of the axon [22]. Once axonal contact is made and
myelination initiated, OLs transport myelin proteins and
lipids to the myelin membrane [26].
2.3. The Development of Glutamate Receptors in Cere-
bral White Matter in the Preterm Period. Given the crit-
ical role of glutamate receptors in mediating excitotoxi-
city, their regional and cellular development is of major
interest in the preterm brain. Several studies of gluta-
mate receptor subtypes have been performed in peri-
natal human brains [27–29], including a comprehensive
cellular localization of alpha-amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA) receptor subtypes in the
human cerebral cortex and white matter from the preterm
period into infancy [29]. Alpha-amino-3-hydroxy-5-methyl-
4-isoxazole-propioinic acid receptor subtypes lacking GluR2
are especially permeable to calcium and therefore likely to
convey increased susceptibility to hypoxia ischemia. From 20
to 37 weeks, pre-OLs, radial glial ﬁbers (RGFs), and subplate
neuronsexpressAMPAreceptorsthatlackGLuR2expression
[29]. The glutamate transporter EAAT2, on the other hand,
is transiently expressed in the cerebral white matter in
the period of vulnerability to PVL and likely increases
the susceptibility of this site to excitotoxicity because it
is a major source of extracellular glutamate complicating
ischemic injury [30]. This transporter is expressed by OLs
but not astrocytes or axons in the preterm white matter [30].
2.4. Development of Microglia in the Cerebral White Matter
in the Preterm Period. Microglia are abundant in the human
forebrain around 16–22 gestational weeks [31–33]. They are
involved in a variety of normal developmental events, such
as axonal development, angiogenesis, and synaptic pruning
[33]. Their density in the cerebral white matter reaches a
peak around the early third trimester and then declines
rapidly after 37 gestational weeks [33]. As the microglial
densitydeclinesinthewhitematter,itincreasesinthecortex,
perhaps reﬂecting continuing migration of microglia [33].
Thus, microglia are transiently elevated in the peak window
of vulnerability to PVL, well situated to become activated
and lead to free radical and cytokine injury to pre-OLs [8].
Of note, O4 OLs in the human cerebral white matter express
interferon-γ receptors, indicating that they are vulnerable to
receptor-mediated mechanisms by cytokines [34].
2.5. Development of Radial Glial Fibers and Astrocytes in the
Cerebral White Matter in the Preterm Period. The last half
of human gestation is a crucial time in astrocyte formation
in the cerebral cortex and white matter. The radial glial
cell originates in the ventricular/subventricular zone and
retains connections with the ependyma and pia [16]; it is
capable of generating neurons and astrocytes [35]. Its long,
thin, and linear processes, that is, RGFs, serve as a guide
for migrating neuroblasts and glial cells [16]. Glutamatergic
neuronsforminthedorsaltelencephalicpalliumandmigrate
a l o n gR G F se a r l yi ng e s t a t i o n[ 36]. In the human brain, in
contrast to the rodent brain, approximately two-thirds of
GABAergic neurons arise from the dorsal telencephalic zone
and migrate along RGFs; the remaining one-third originates
in the ganglionic eminence and migrates tangentially to the
cortex[37].From19to30weeks,RGFsareabundant;around
30-31 weeks, they begin to transform into ﬁbrous astrocytes4 Neurology Research International
inthe whitematterandfrom30 weeks toterm gestation(37–
41 weeks), they progressively disappear as the white matter
becomes increasingly populated with transformed astrocytes
[38–40].Byterm,RGFscompletelydisappear,therebydeﬁni-
tivelymarkingtheendofradialmigration.Fibrousastrocytes
in the white matter also form from glial precursors that
migrate outward from the ventricular/subventricular zone
independent of RGFs [16]. Reactive gliosis with gemistocytic
morphology and GFAP-positive immunostaining begins
around midgestation in the human brain [7].
2.6. The Development of Antioxidant Systems in the Cerebral
White Matter in the Preterm Period. The human preterm
brain is susceptible to free radical injury in hypoxia ischemia
because of a relative developmental deﬁciency in antioxidant
enzymes. These enzymes include the superoxide dismutases-
1 and -2 for the conversion of superoxide anion oxygen to
hydrogen peroxide and catalase and glutathione peroxidase
for the breakdown of hydrogen peroxidase. In the cerebral
white matter of the preterm infant, the expression of both
superoxide dismutased signiﬁcantly lags behind that of
catalase and glutathione peroxidase [41]. These enzymes are
all expressed by OLs and astrocytes in the preterm brain and
exceed adult levels at 2–5 postnatal months, the peak period
of active myelin sheath synthesis in cerebral white matter
[41]. Indeed, human myelination with the rapid production
of cellular membrane is associated with the “physiological”
generation of free radicals resulting in lipid peroxidation
[42].
2.7. Axonal Development in the Cerebral White Matter in
the Preterm Period. T h es e c o n dh a l fo fh u m a ng e s t a t i o ni s
characterized by axonal elongation from the early migrating
pyramidalneur ons,aswellasfr omc orticalaﬀerentsfromthe
thalamus and other cortical and subcortical structures [43].
Central axons elongate, search out their proper targets, and
establish synaptic contacts; initial axonal excess is followed
by axonal elimination or pruning, leading to reﬁnements in
connectivity [26]. The expression levels of growth-associated
protein-43(GAP-43),aneuronalmembranephosphoprotein
and marker of axonal elongation, are low in the human cere-
bral white matter at 19-20 weeks, increase approximately 3-
foldwithintwoweeks,peakattermatapproximately5-times
adult levels, and decrease dramatically at approximately 17
postnatal months, with adult levels attained in the second
year [44]. From 14 gestational weeks onward, so-called
“crossroads” of intersecting projection and associative axons
are present in the periventricular zones, directly adjacent to
the lateral ventricles, coinciding with the sites of predilection
for focal necrosis in PVL [45]. Because of the complexity
of the axonal pathways in these discrete and restricted loci,
discrete lesions within them are postulated to result in
diverse and multiple functional impairments simultaneously
in preterm survivors [44].
2.8. Neuronal Development of the Cerebral Cortex in the
Preterm Period. During the last half of gestation, the neo-
cortex transforms from an undiﬀerentiated cortical plate to
a highly specialized structure [7, 16, 46–48]. Around 30
gestational weeks, the cortical plate becomes comprised of
six layers in which each layer is characterized by a speciﬁc
composite of diﬀerentiating pyramidal and nonpyramidal
neurons [46]. The cortex increases in thickness due to
striking increases in the neuropil, for example, neuronal cell
size, dendritic arborization, spine formation, and arrival of
preterminal aﬀerents [7, 16, 46–48]. Indeed, the number of
speciﬁc gene expression and alternative splicing patterns are
large and associated with distinct regions and developmental
processes [49]. Relative to excitotoxicity, GluR2 is low in the
pyramidal and nonpyramidal neurons in the cerebral cortex
during the term neonatal period [29].
2.9. Late Development of the GABAergic System in the
Cerebral Cortex in the Preterm Period. A deﬁning feature
of cortical development in the human preterm period is
the late development of the GABAergic interneurons that
play a key role in cortical speciﬁcation, output, and synaptic
plasticity[16,36,50,51].Atleast20%ofGABAergicneurons
migrates through the white matter to the cerebral cortex over
late gestation [50]. This migration peaks around term and
then declines and ends within the ﬁrst 6 postnatal months;
in parallel, the GABAergic neuronal density increases in
the cortex over late gestation, peaks at term, and declines
thereafter [50]. From midgestation to infancy, the pattern
of GABAA receptor binding also changes from uniformly
low across all cortical layers to high levels concentrated in
the middle laminae [50]. This developmental proﬁle may
reﬂect the ingrowth of glutamatergic thalamocortical ﬁbers
during this time period with a parallel upregulation of
inhibitory (GABAergic) modulation in the middle laminae
tocounterbalancetheincreaseinexcitatoryinputsduringthe
preterm period. The GABAA receptors are likely excitatory
because of relatively high intracellular levels of chloride.
The latter occurs because of a developmental imbalance of
the chloride importer (NKCC1) and the chloride exporter
(KCC1). In the human cerebral cortex, the expression of
NKCC1, causing chloride inﬂux, rapidly increases from 20
gestational weeks to term and then dramatically decreases,
reaching a plateau after 4 postnatal months [52]. The
expression of KCC2, causing chloride inﬂux, on the other
hand, is low during the preterm period but increases
dramatically postnatally to adult levels [52]. Thus, in the
preterm period, GABA agonists lead to chloride eﬄux and
depolarization/excitation, rather than the normal chloride
inﬂux and hyperpolarization/inhibition.
2.10. Development of Protoplasmic Astrocytes in the Cerebral
CortexinthePretermPeriod. Inthecerebralcortex,astrocyte
precursors that have migrated upward along the RGFs
to Layer I, diﬀerentiate and send processes towards the
developing cortical blood vessels, and gradually transform
intotheprotoplasmicastrocytesofthecortex[16].Thisevent
occurs “late”, that is, after the completion of the migration
of neuroblasts destined to form cortical neurons. These
astrocytes express the glutamate transporters EAAT1 and
EAAT2butnotglialacidicprotein(GFAP)inthelatepretermNeurology Research International 5
period [53]. Discrete EAAT1/EAAT2 astrocytic “patches”
appear in the developing cortex in the late preterm period
[53]. The patches may reﬂect nonoverlapping astrocytic
territories that potentially contribute to the synchronization
of neurons [53].
2.11. Development of the Subplate Region in the Preterm
Period. Subplate neurons are among the ﬁrst generated
neurons of the neocortex and come to lie immediately
beneath the developing cortical plate where they form
part of the early neocortical circuitry [54, 55]. During
early development, subplate neurons play a critical role in
the establishment of connections between the cortex and
thalamusandcorticallamination[54,55].Theseneuronsare
also critical in the establishment of axons destined to the cor-
tex from the contralateral cerebrum (commissural-cortical
ﬁbers) and from unilateral cortical sites (corticocortical
association ﬁbers). There is no available immunomarker that
speciﬁcally labels human subplate neurons in tissue sections.
Their phenotype is deﬁned by morphology, location, and
connectivity with the cortical plate. In the human subplate
region, fusiform, granular, unipolar, bipolar, multipolar, and
invertedpyramidalneuronshavebeenobserved[54,56].The
speciﬁcfunctionofeachmorphologicalsubtypeisunknown.
Glutamatergic, GABAergic, and other transmitter-speciﬁc
neurons, transporters, and receptors have also been observed
in the human subplate region [29, 50, 51, 56]. Kostovic
and Rakic divide the developmental stages of the human
subplate zone into the presubplate stage at around 12-13
gestational weeks, the subplate formation stage around 12–
15 weeks, the subplate stage around 15–35 weeks, and the
subplate dissolution stage beyond 35 weeks [54]; the latter
two stages coincide with the period of EP. In the subplate
stage (15–35 weeks), the subplate serves as a “waiting”
compartment for the competition, segregation, and growth
of aﬀerents originating from the thalamus, brainstem, basal
forebrain, and ipsi- and contralateral cerebral hemisphere
[43, 54]. During this stage, the histochemical stain acetyl-
cholinesterase highlights cholinergic terminals arising from
the basal forebrain [54]; around midgestation, this stain
indicates that the subplate zone is four times thicker than the
corticalplate[54].Aftertheincomingﬁbersenterthecortical
plate around 32 weeks, the subplate zone almost completely
disappears, leaving only a “vestige” of neurons cells scattered
throughout the subcortical white matter, that is, so-called
interstitial neurons, which nevertheless contribute to the
modulation of adult cortical processing [57].
2.12. The Development of SubcorticalStructures in the Preterm
Period. The involvement of the basal ganglia, thalamus,
hippocampus, cerebellum, and brainstem in EP suggests
that all of these gray matter sites have developmental
factors that increase susceptibility to glutamate, free radical,
cytokine, and metabolic insults. Nevertheless, information
is relatively limited about these factors in the human
preterm brain. Transient expression of glutamate receptors
has been described in the developing human basal ganglia
[28] and brainstem [58, 59]. The expression levels and
cellular localization of several antioxidant enzymes have
also been deﬁned in the basal ganglia and brainstem by
immunohistochemistry [60].
3. The Pathology of the Encephalopathy
of Prematurity
3.1. Periventricular Leukomalacia (PVL). This lesion is the
major white matter component in EP and is deﬁned
as focal periventricular necrosis associated with reactive
gliosis and microglial activation in the surrounding cerebral
white matter [3, 7]. The necrotic foci likely represent a
core infarct with destruction of all cellular elements [3,
7, 61], while the astrocytic and microglial response in
the surrounding white matter represents the penumbra
with less severe and potentially reversible ischemic injury
[3]. The necrotic foci progress from coagulative necrosis
(characteristicofthehistologyoftissueischemiainalltissues
[3]), with hypereosinophilia, nuclear pyknosis, and axonal
spheroids, followed by organizing necrosis with reactive
gliosis, macrophagocytic inﬁltration and tissue disintegra-
tion, and then end-stage cystic formation and gliosis [3, 7].
Importantly, the necrotic foci are not always apparent upon
macroscopic examination. In autopsy studies in our hospital
from the modern era of intensive care, 46–82% of PVL cases,
depending upon the dataset, have only microscopic necrotic
foci (with macrophagocytic inﬁltration) that measure less
than 2mm in diameter [9, 46, 62]. Moreover, neuroimaging
studiesoverthepast10–15yearsdemonstratethatcysticPVL
has declined in incidence and noncystic PVL has become the
dominant lesion, accounting for more than 90% of PVL and
occurring in approximately 50% of very low birth weight
infants[2].Nevertheless,visuallyobviousfociofnecrosis,so-
called “white spots”, as well as cysts greater than 2 millimeter
in diameter are still detected at autopsy [9, 46, 62]. Diﬀuse
white matter gliosis without periventricular necrotic foci
occurs in preterm brains [63] but its relationship to PVL
is uncertain, for example, whether or not it represents the
least severe end of a spectrum of ischemic injury to the
premyelinatedwhitematter,withPVLatthemostsevereend.
Nevertheless,neuronal lossin graymattersites occursalmost
exclusively in association with PVL and not with diﬀuse
white matter gliosis [9], suggesting that PVL is the hallmark
of EP and that injury that leads to focal necrosis in the white
matter and neuronal loss in the gray matter is the deﬁning
event of EP.
The pathogenesis of PVL involves acute loss of pre-OLs
[64, 65]; some OL cell bodies appear to survive with loss of
cell processes [66], others with morphological dysfunction
in myelin formation [66], as well as hypomyelination
[67]. Immunocytochemical analysis using an antibody to
Olig2, a pan-OL lineage marker, indicates no signiﬁcant
diﬀerence in Olig2 cell density in the periventricular or
intragyralwhitematterbetweenPVLcasesandcontrols[66].
Nevertheless, early lineage markers are needed to determine
if there is arrested OL maturation with dominance of pre-
OLs over mature OLs. Qualitative abnormalities of MBP
staining in both the diﬀuse and necrotic foci of PVL occur6 Neurology Research International
despite preserved OLIG2 cell density [66]. They include
excessive MBP immunostaining in enlarged OL perikarya
that presumably reﬂects a functional derangement in MBP
transport from its site of production in the OL cell body
to the OL processes [66]. Free radical injury to pre-OLs
in PVL is indicated by immunocytochemical evidence for
protein nitration and lipid peroxidation of pre-OLs in the
diﬀusely gliotic component of PVL [64]. In addition, F(2)-
isoprostanes, an arachidonate metabolite/lipid peroxidation
marker of oxidative damage, is signiﬁcantly increased in the
white matter of early PVL cases [65]. The end-stage of PVL is
delayed or hypomyelination of the cerebral white matter and
compensatory ventricular enlargement [7].
3.2. Gray Matter Lesions in EP. Neuronal loss and/or gliosis
are the histopathologic hallmarks of gray matter injury in EP
and occur in virtually all gray matter sites, albeit in variable
combinations [9]. Over one-third of PVL cases demonstrates
gray matter lesions characterized by neuronal loss and/or
gliosis [9]; microglial activation is oftentimes striking. Of
note, more reﬁned techniques, such as analysis of dendritic
and spine number and morphology, may ultimately detect
neuronal deﬁcits at the subcellular (and molecular) levels.
Theincidenceofneuronalloss,asassessedsemiquantitatively
in tissue sections, is 38% in the thalamus, 33% in the
globus pallidus and hippocampus, and 29% in the cerebellar
dentate nucleus [9]. Gliosis without obvious neuronal loss
is more common than combined neuronal loss and gliosis,
occurring in the thalamus (56% of PVL cases), globus
pallidus (60%), hippocampus (47%), basis pontis (100%),
inferior olive (92%), and brainstem tegmentum (43%) [9].
In a histopathologic survey of brain injury in very low
birth weight infants, the frequency of neuronal loss (sites
unspeciﬁed) is reportedly less than cerebral white matter
abnormalities [68]. The basis of neuronal injury in PVL
may be heterogeneous, as suggested in the thalamus [69].
At this site, injury occurs in four diﬀerent patterns, that is,
diﬀuse gliosis with or without neuronal loss, microinfarcts
with focal neuronal loss, macroinfarcts in the distribution
of the posterior cerebral artery, and status marmaoratous
[69]. These diﬀerent patterns likely each reﬂect separate
mechanisms, including diﬀuse hypoxia ischemia and focal
arterialembolism[69],aswellaspotentialdiﬀerenttemporal
characteristics of the responsible insults.
The cerebellum in the preterm infant demonstrates
bilateral, symmetric deﬁcits in hemispheric volume without
overt parenchymal hemorrhage or infarction [60–72]. This
reduced volume is commonly associated with intraventric-
ular or subarachnoid hemorrhage [72]. Moreover, cere-
bellar underdevelopment is associated with supratentorial
lesions, especially PVL and posthemorrhagic infarction,
suggesting the possibility of transsynaptic mechanisms in its
pathogenesis via corticopontocerebellar pathways [70, 72].
Yet, neuroimaging studies also indicate a gradual deﬁcit
in cerebellar volume in preterm infants associated with
infratentorial hemosiderin deposition in the majority of
cases [72]. Thus, it has been postulated that blood products
(hemosiderin/nonheme iron) in the cerebrospinal ﬂuid lead
to cerebellar underdevelopment due to their toxic eﬀects
upon the proliferating granule precursor cells of the external
granular layer which are located directly at the interface
with the subarachnoid space and which migrate inward to
form the internal granular layer [72]. Nevertheless, this idea,
based upon neuroimaging studies, has not been veriﬁed
by quantitative analysis of the cell number of the internal
granular layer. Indeed, semiquantitative analysis of the
cerebellum has revealed moderate loss of cortical neurons in
24% of cases with PVL and moderate loss of dentate neurons
in 29% of cases [9] in association with reactive astrocytes.
Thus, the neuropathologic features (notably gliosis) suggest
an acquired insult leading to cerebellar atrophy rather than
underdevelopment as the basis of the small size of the
cerebellum on neuroimaging studies. Yet, the distinction
between atrophy and underdevelopment is diﬃcult in the
developing cerebellum in which migration from the external
totheinternalgranularlayerisprotractedoverthelasthalfof
gestation into infancy. That is, a particular insult may simul-
taneously lead to atrophy with drop out of cells already at
their proper address (inciting gliosis) and underdevelopment
due to disruption of still migrating cells and an incomplete
complement of neurons. Indeed, the pathology of the
cerebellum epitomizes the so-called “complex amalgam” of
EP where developmental and destructive processes intersect
[2]. In regards to the cerebellar relay nuclei, it is uncertain
if the neuronal loss in the basis pontis and inferior olive,
the major cerebellar relay nuclei, which is seen in 21% of
PVL cases [9], is primary or secondary to transsynaptic
degeneration.
3.3. Deﬁcit of Neurons in the Subplate Zone and White
Matter in EP. Not only is there damage to neurons in gray
matter sites but also to neurons located in the white matter
and subplate region. The density of granular neurons is
signiﬁcantly reduced in the periventricular and central white
matter and subplate region in PVL [56]. These neurons
are likely late migrating GABAergic neurons and/or non-
GABAergic constituents of the subplate region and intersti-
tial white matter [56]. In regard to the former possibility, a
reductioninthedensityofGAD67-immunopositive neurons
and neurons expressing the GABAAα1r e c e p t o rh a sb e e n
reported in human perinatal white matter lesions (with
and without focal necrosis) [51]. The granular neurons
expressedGAD67/65,amarkeroftheGABAergicphenotype,
but not markers of neuronal and glial immaturity (Tuj1,
doublecortin [DCX], or NG2) [56]. Notably, in contrast to
granularneurons,thereisnotaconsistentdeﬁcitinunipolar,
bipolar, multipolar, or inverted pyramidal neurons in the
white matter or subplate region in PVL [56]. The ﬁnding of
reduced density of white matter neurons in the necrotic foci
in PVL is not unexpected since necrosis involves destruction
of all cellular elements. The deﬁcit in the granular neurons
distant from the focally necrotic lesions, that is, in the
subplate region, on the other hand, is of major interest
because it occurs presumably in zones of less severe insult.
The preferential damage to granular neurons, including
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subtype is exquisitely sensitive to hypoxia ischemia. In
humans, approximately one-third of GABAergic neurons
arises from the ganglionic eminence [37]. In the study of
reduced granular cells in the white matter and subplate
region, approximately one-third of the PVL cases had
germinal matrix hemorrhages in the ganglionic eminence,
raising the possibility that the reduction in neuronal density
in the white matter in these PVL cases was accentuated by
mechanical damage to the GABAergic neurons originating
in this site. It has recently been reported that germinal
matrix hemorrhage is associated with a marked decrease in
proliferating cells, as identiﬁed by Ki67 immunoreactivity
and not an increase in apoptosis, in survivors over 12 hours
[5]. Yet, there was no signiﬁcant diﬀerence in the granular
neuronal density in the white matter between PVL cases with
and without ganglionic hemorrhages.
3.4. Damage to RGFs in EP. Radial glial ﬁber damage could
adversely aﬀect radial neuronal migration with secondary
maldevelopment of the vertical columns of the cerebral
cortex. This idea has not been rigorously tested, however,
in the preterm brain with the necessary tissue methods
to deﬁne quantitative derangements in cortical mini- and
macrocolumn formation in postmortem brains. Damage to
RGFs may also potentially impair astrocytic development,
as ﬁbrous astrocytes in the white matter develop from the
transformation of RGFs, and protoplasmic astrocytes in the
cortex transform from Layer I astrocytes following RGF
migration [16] .Ad e ﬁ c i ti nﬁ b r o u sa n d / o rp r o t o p l a s m i c
astrocytes in EP may be potentially masked by gliosis, as
there are no quantitative criteria for an “adequate” astrocytic
response.Nevertheless,reactiveastrocytesinEPdemonstrate
evidence of oxidative and nitrative stress, which is potentially
primary and could lead to an “inadequate” glial response
[64, 73]. Indeed, so-called “acutely damaged glia” in PVL
[63] may represent astrocytes undergoing cell death. Given
theroleofastrocytesinprotectingagainstischemicinjuryvia
glutamate uptake and in orchestrating cytokine responses,
damage to them secondary to potential RGF injury in
EP potentially is likely to be especially deleterious. The
delineationofRGFpathologyinEPisanimportantdirection
for future research.
3.5. Diﬀuse Axonal Injury in the Cerebral White Matter in
EP. With β-amyloid precursor protein, axonal spheroids
are detected within the necrotic lesions of PVL, whether
focal or large [74]. With the apoptotic marker fraction,
on the other hand, diﬀuse axonal injury is detected in
the white matter distant from acute or organizing necrotic
foci, suggesting a widespread axonopathy in PVL [62]. This
diﬀuse axonal damage may reﬂect secondary degeneration
of thalamocortical aﬀerents complicating primary thalamic
neuronalloss.Alternatively,itmaybeprimaryduetohypoxic
ischemic or inﬂammatory injury directly to the axon, with
secondary impairments in axonal-OL interactions in the
initiation and maintenance of myelination. Irrespective of its
pathogenesis, widespread axonal damage likely contributes
to the reduced white matter volume and callosal thinning
in end-stage PVL. Axonal injury throughout the diﬀuse and
focal components of PVL may also lead to architectonic
changes in the overlying cerebral cortex [46, 75].
3.6. Reactive Gliosis and Activated Microglia in the Cerebral
White Matter in EP. Reactive gliosis and activated microglia
are the two major inﬂammatory components of PVL [3,
4, 7]. Presumed to be initially protective against pre-OL
cell damage, they carry the potential for compounding
tissue injury when the insult is prolonged and/or severe.
Reactive gliosis in PVL is preferentially located in the deep
as compared to intragyral white matter [64] and thereby
deﬁnes injury in the vascular distal ﬁelds of the cerebral
white matter. Activated microglia likewise conform to this
regional distribution, while macrophages are prominent in
the organizing necrotic foci of the periventricular regions [3,
5, 7]. Both astrocytes and microglia/macrophages produce
inﬂammatory cytokines, and immunocytochemical studies
in PVL demonstrate increased cytokine expression within
them as a distinctive feature of the histopathology [34, 76].
Notably, reactive astrocytes in PVL express interferon-γ and
thusareapotentialsourceforthistoxiccytokine,particularly
topre-OLscomparedtomatureOLs[77].Reactiveastrocytes
and microglia/macrophages also help protect pre-OLs from
excitotoxic injury by the upregulation of the glutamate
transporter EAAT and uptake of excessive tissue glutamate,
as suggested by the ﬁnding that the percentage of EAAT2-
immunopositive astrocytes is increased in PVL compared to
control white matter, and macrophages in the necrotic foci
express EAAT2 [78]. Yet, reactive astrocytes and microglia
may contribute to free radical injury in PVL, as indicated by
intense expression of inducible nitric oxide synthase (iNOS),
a marker of nitrative stress, in reactive astrocytes in the acute
through chronic stages of PVL, and in activated microglia
primarily in the acute stage, the latter observation suggesting
an early role for microglial iNOS in the pathogenesis of PVL
[73]. In addition, the density of iNOS-immunopositive cells
is signiﬁcantly increased in the diﬀuse component [73].
3.7. Neural Repair in EP. Evidence is mounting that tissue
repair is underway in EP within the neonatal period, that
is, within the period of the inciting insult(s). In this
regard, Olig2 cell density at the necrotic foci is increased in
PVL cases compared with that in sites distant from these
foci, suggesting that OLs are migrating to the ischemic
core to replenish OL cell number [66]. In PVL, the stem
cell immunomarker to nestin demonstrates its increased
expression in glia and neurons, attributed to nestin upreg-
ulation in response to injury rather than regeneration of
new cells [79]. Using DCX immunopositivity as a marker
of postmitotic migrating neurons, we found signiﬁcantly
increased densities of DCX-immunopositive cells in PVL
cases compared to controls in the subventricular zone,
necrotic foci, and subcortical white matter in the perinatal
time window, that is, 35–42 postconceptional weeks [80].
These increased DCX-immunopositive neurons may be en
route to replenish the loss of white matter neurons. Their
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the regenerative capacity originates in this germinal site
[81]. Successful incorporation of the DCX-immunopositive
cells into the neuronal circuitry of the white matter in PVL
will ultimately depend upon timing and extent of injury,
as well as the availability of neurotropic factors necessary
for cellular diﬀerentiation and the formation of functional
circuits.
4. The Bridge between Human and
AnimalResearch in
the Encephalopathy of Prematurity
4.1. Strengths of Human Neuropathologic Studies in Transla-
tional Research in EP. Insights from such studies are crucial
to translational research because they shape the relevant
hypotheses for animal models by deﬁning the vulnerable
cell populations and brain regions, pathogenic molecules,
and cellular features of the inﬂammatory and reparative
responses. Human studies have taught us that: (1) pre-
OLs, neurons, and axons in combination are the key cellular
substratesatriskinEP;(2)thecerebralwhitematter,cerebral
cortex, thalamus, basal ganglia, cerebellum, and brainstem
are the key brain regions involved; (3) cerebral white matter
damage involves micro- and/or macrofoci of necrosis with
macrophages in combination with diﬀuse reactive gliosis
and microglial activation and axonal damage; (3) reactive
astrocytes and activated microglia are critical components
of both gray and white matter injury. Moreover, human
neuropathologic studies provide insights into the anatomic
substrate of the cognitive, emotional, and behavioral disor-
ders in preterm survivors that are not always forthcoming
in animal models, given the profound species diﬀerences in
executive functions and higher aﬀective processing. Indeed,
the spectrum of neuronal and axonal lesions in EP elucidates
the basis of the complex cognitive deﬁcits in preterm
survivors and indicates that these deﬁcits are not based upon
white matter damage alone, but rather, likely result from
simultaneous damage to diverse nodes in cognitive process-
ing, that is, the corticothalamic-commissural-associative-
subplate network [9, 46, 51, 56, 69, 75]. The ﬁnding of
thalamic damage in the mediodorsal nucleus and reticular
nucleus associated with PVL, for example, may help explain
the clinical observations of deﬁcits in working memory
and state regulation, respectively, in preterm survivors [69],
the ﬁnding of cerebellar damage helps explain the autistic
behaviors [12, 72], and the ﬁnding of secondary cerebral
cortical changes overlying necrotic white matter lesions, the
seizure disorders, and cortical-based cognitive impairments
[75]. In addition, the tissue demonstration of neuronal loss
and/or gliosis in gray matter sites provides a starting point
for establishing the cellular underpinnings of gray matter
volume deﬁcits deﬁned by neuroimaging studies [10–12],
with the need for future investigations into the potential
contributions of associated neuropil (synaptic) loss. The
humanneuropathologicstudiesalsoindicatetheintersection
of destructive injury and altered developmental trajectories,
for example, acquired damage to axons traversing the
cerebral white matter to and from the cortex and subsequent
trophic neuronal changes in the overlying cortex [46, 75],
cerebellar atrophy/underdevelopment [70–72].
4.2. Strengths of Studies in Animal Models in Translational
Research in EP. Despite their many strengths, human neu-
ropathologic studies have several drawbacks that mandate
their performance in unison with animal studies in order
to establish the “complete picture” of EP. Indeed, the
examination of human tissue sections under the microscope
providesonlyasinglesnapshotinwhichthedynamicprocess
is frozen at one single time point and the distinction between
primary and secondary features is impossible. Moreover,
while the patterns of injury in human tissue sections can
suggest a mechanism, for example, coagulative necrosis and
ischemia[3],thepatternsarenotalwayspathognomonicand
therefore cannot specify the mechanism(s) precisely. Thus,
animal models are essential for the determination of cellular
and molecular mechanisms critical for the development of
therapeutic interventions in patient care. Examples include
the testing of diﬀerent drugs in the prevention or amelio-
ration of white matter damage in rodent models [81–84].
The strength of animal models in deciphering mechanisms
is well illustrated in studies addressing the relative roles
of hypoxia ischemia and infection/inﬂammation in pre-OL
cell death in perinatal white matter damage. In a variety
of small and large animal models, hypoxia ischemia has
been shown to lead directly to pre-OL damage [81–88]. Yet,
several animal models indicate that hypoxia ischemia alone
is not always suﬃcient to cause brain injury, but rather,
results in signiﬁcant injury only when combined with an
infectious/inﬂammatory insult, notably pretreatment with
lipopolysaccharide (LPS) [8, 88, 89]. When LPS administra-
tion is followed by hypoxia ischemia in a perinatal murine
model, for example, pre-OL death occurs acutely and is then
followed by decreased mature, MPB-expressing OLs [88].
Chronically administered LPS, however, does not induced
hypoxemia in the fetal sheep model but also causes white
matter injury, with axonal damage, activated microglia, and
OL injury [90], albeit to less severe degrees than when
applied acutely [91]. Thus, animal models allow for testing
hypotheses about causal factors alone and in combination,
the latter more faithfully mimicking the complex clinical
courseofpreterminfantswithmultiplesimultaneousinsults.
Nevertheless, animal models also have limitations for
mechanistic testing. Cell culture and slice systems are needed
to determine the molecular and biochemical eﬀects of injury
upon single cell types, as exempliﬁed by the determination
of the basis of the vulnerability to glutamate and free radical
toxicity of pre-OLs compared to mature (myelinating) OLs
[8, 92–95] and the eﬀects of diﬀerent trophic factors on
OLproliferation,diﬀerentiation,andmyelinsheathsynthesis
[96].
An additional strength of animal models is that they
allow for elucidation of evolution of the histopathologic
changes though the sequential examination of brains from
a cohort of animals sacriﬁced at diﬀerent time points
following a common insult [83, 87]. This approach is well
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following uterine artery ligation in a rat model in which cell
death, as deﬁned by TUNEL-positivity at P3, was followed
by O4 cell loss at P7, microglial activation, and then reactive
gliosis in the cerebral white matter, with the persistence
of impaired myelination into adulthood [87]. In this way,
we learn that apoptosis is involved in pre-OL loss and
precedes cell dropout, and that pre-OL damage precedes
and therefore potentially incites the inﬂammatory responses
(microglial and then astrocytic activation) in the early stages.
Animal models can also lead to novel insights into molecules
critical to human lesions but not originally recognized in
the lesions per se, thereby providing new leads for human
investigation. The role of A1 adenosine receptors in the
pathogenesis of preterm white matter damage, for example,
was not suggested from human neuropathologic studies
but rather, from animal models. In a rat model in which
hypoxia ischemia leads to pre-OL injury at P3-P12, cerebral
hypomyelination was prevented by the administration of
caﬀeine [97]. The postulated mechanism for the caﬀeine
beneﬁt relates to the presence of A1 adenosine receptors on
pre-OLs which when activated inhibit pre-OL maturation;
caﬀeine, which blocks A1 adenosine receptors, may in
turn remove the maturation block [97]. The relevance of
molecules originally discovered in animal lesions to human
pathology is determined by their demonstration in human
lesions with immunocytochemistry or other applied tissue
methods. In this way, animal models “feed back” to the
human condition and expand upon its elucidation in new
ways. It is important to demonstrate with human tissue
methods the expression of adenosine receptors by human
pre-OLs to conﬁrm the relevance and ultimate therapeutic
potential of adenosine receptor blockage in human PVL.
Similarly, the unanticipated observation in the sheep model
that the vulnerability of the deep white matter to hypoxia
ischemia is related to the increased spatial concentration of
a susceptible population of pre-OLs and not to a preferential
reduction in cerebral blood ﬂow compared to the intragyral
white matter or cortex [98, 99] needs to be pursued in
human white matter by studies of the quantitative distri-
bution of pre-OLs in periventricular, deep, and intragyral
white matter zones relative to each other to determine the
relevance of the animal discovery to human pathogenesis.
Nevertheless, these sheep studies corroborate the role of
ischemia in the deep white matter to the genesis of pre-OL
injury.
4.3. Types of Animal Models for Translational Research in
EP. Multiple animal models of perinatal brain injury are
currently available, generally with the studies focused to date
uponwhiteor graymatterinjury,rarelybothincombination.
Several comprehensive reviews delineate the pros and cons
of the diﬀerent (small and large) animal models relative
to preterm brain injury [96, 100–110]. The strengths of
rodent models include a comparable timetable of OL lineage
in the cerebral white matter, relative ease and low cost
of experimental manipulations, and capability to utilize
genetically engineered (knockout) mice. Their disadvantages
include the paucity of cerebral white matter and the lack
of cortical gyration. Moreover, there are key intrinsic dif-
ferences in aspects of cerebral development between human
and rodent. A relevant example in this context is the origin
of GABAergic neurons, for example, nearly entirely from
the ganglionic eminence in the rodent but principally from
the dorsal pallium in the human [37]. The strengths of
large animals, on the other hand, include major structural
similarities with the developing human brain, including in
gyration and the sequence of OL diﬀerentiation, comparable
scaling of gestational age relative to brain development, the
capability for invasive instrumentation relative to measures
of cerebral blood ﬂow and cardiorespiratory parameters,
and closer analogy of neurological consequences to those
in human preterm infants. Their disadvantages include the
need for considerable expertise and resources in large animal
husbandry and surgical and supportive procedures.
4.4. Caveats in Modeling White Matter Injury in the Preterm
Infant. As noted above, the clinical picture of preterm
white matter injury is changing such that cystic PVL is
now uncommon and has been replaced by a “diﬀuse”
lesion in neuroimaging studies in living infants. Studies in
sheep suggest that cystic PVL results from severe ischemic
insults, whereas diﬀuse lesions result from lesser degrees
of ischemia [98, 99]; thus, the decline in cystic PVL in
the neonatal nursery may reﬂect in part improvements
in the management of the cardiorespiratory disorders of
prematurity. Because cystic PVL may indeed represent the
severe end of the spectrum, it is nevertheless common in
fatal human cases that are presumably the most severely
challenged. Still, the presence of cystic PVL at autopsy in the
current era cannot be ignored because it indicates that the
responsible pathogenic factors in the past era (when cystic
PVLwasthedominantwhitematterlesionbyneuroimaging)
are still operative.
What is the neuropathology of the “diﬀuse” lesion seen
by neuroimaging studies in the preterm infant today? Based
upon human autopsy studies, this lesion is comprised, in our
opinion, of foci of microcystic necrosis in the deep white
matter (with these small cysts below the detection capability
of modern neuroimaging techniques) in association with
diﬀuse microglial activation, gliosis, and axonal damage
(Figure 1). Precise correlations between neuroimaging and
autopsy ﬁndings in the same infant at the time of death
are needed for veriﬁcation that this microcystic lesion is
in fact the diﬀuse lesion of neuroimaging studies. In a
fetal sheep model, however, high-ﬁeld MRI of chronic
perinatal white matter injury indicates correlations between
particular patterns of images with microscopic necrosis and
reactive gliosis and with pre-OL maturation arrest upon
histopathologic examination [111]. In essence, microcystic
PVL (with diﬀuse gliosis and microglial activation) remains
a major ﬁnding in the preterm brain in active pediatric
neuropathology services today. Until proven otherwise, the
hallmark of preterm white matter injury remains focal
necrosis with macrophages, and its replication in animal
models, as well as its relationship to pre-OL injury, should
be sought in translational research.10 Neurology Research International
∗
∗
∗
∗
CC
(a) (b) (c)
(d)
Figure 1: White matter damage in the human preterm brain is characterized by microscopic foci of necrosis and diﬀuse reactive gliosis,
microglial activation, and axonal damage. (a) Camera lucida drawing of the distribution of microcysts (∗) and axonal fragments (arrows) in
the posterior frontal white matter (level of the body of the corpus callosum [CC]). In the white matter distant from periventricular foci of
necrosis is reactive gliosis, as demonstrated by the immunomarker glial ﬁbrillary acidic protein (b), microglial activation, as demonstrated
by the immunomarker CD68 (c), and axonal injury, as demonstrated by the immunomarker fraction (d).
4.5. The Selection of an Animal Model in EP. The question
arises: should an animal paradigm model the entire neu-
ropathologic spectrum of EP and thereby cell interactions in
pathogenesis, or rather, model one feature of the spectrum,
for example, pre-OL cell death, in search of a cell-speciﬁc
mechanism? The answer is obviously that both types of
models play valuable and complementary roles. Yet, it is
increasingly clear over the last decade from neuroimaging
and neuropathologic studies that human preterm injury is
a complex spectrum of pre-OL, neuronal, and axonal injury
in multiple brain regions, as well as distinct inﬂammatory
responses, reparative events, hemorrhages, and focal infarcts
[2, 3, 6], and the interrelationships of these pathologic
processes need to be determined to elucidate the shared
mechanisms and sequential cascade of the tissue reactions.
It is critical, for example, to examine pre-OL and axonal
damage in conjunction with each other to determine the
molecular inﬂuences of injured pre-OLs and axons upon
each other in the initiation and progression of myelin
sheath wrapping. While human studies indicate both focal
and diﬀuse axonal injury in PVL [7, 62, 73, 74], such
injury is often not addressed in animal models in the same
brains that undergo intensive investigations of pre-OLs. In
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axonal integrity was assessed with the antineuroﬁlament
antibody SMI-312, axonal degeneration or reductions in
axonal density were not observed, whereas pre-OLs were
present that failed to initiate myelination [86]. The apparent
resistance of the axons to hypoxic ischemic injury in this
model was likened to that of murine axons at P3 in an
oxygen glucose deprivation model [112]. In a large animal
(sheep) model, however, axonal degeneration was apparent
with prolonged ischemia [98], providing insight into the
potential basis of the widespread axonal damage in human
preterm infants [73].
Still, the major focusin animal models related to preterm
brain damage to date has been upon white matter injury
and the cellular mechanisms of pre-OL injury almost in
isolation for a variety of historical reasons, as recently
reviewed [4]. This focus illustrates in large part the cell-
speciﬁc approach to animal models, as they address the
hypothesis that hypoxia-ischemia causes pre-OL cell death
and hypomyelination. The major criteria for an animal
model of white matter injury are thus a cellular sequence of
OL lineage similar to that of human preterm white matter
and an analogous developmental window when pre-OLs
dominate. Various hypoxic-ischemic models have demon-
strated the death and dropout of pre-OLs with O1 and O4
immunomarkers, the regeneration and arrested maturation
of pre-OLs with proliferative and early OL markers, and
hypomyelination by loss of MBP staining [81, 85, 86, 88,
97–99]. Thus, these models have successfully delineated
the “natural history” of pre-OL damage upon exposure to
hypoxia ischemia and have established unequivocally the
role of this insult in white matter injury. Moreover, they
have provided an important explanation for the observation
in human PVL that the density of OLs labeled with the
immunomarker OLIG2 is not decreased, that is, this marker
labels all stages of OL lineage and therefore this preservation
of OL density may reﬂect proliferation of pre-OLs with
arrestedmaturationwithdominanceofpre-OLsovermature
OLs [66]. Animal models have also solidiﬁed the role of
glutamate and free radicals in the tissue injury. In a preterm
fetal sheep model of bilateral carotid occlusion, for example,
extracellular excitatory aminoacids and malondialdehyde
(but not 8-isoprostane) were signiﬁcantly increased in the
periventricularwhitematterwithapeakat2-3daysfollowing
occlusion [113].
Yet, the pathology of white matter damage in the human
infantisfarmorecomplexthanpre-OLdamageonly.Indeed,
the hallmark of PVL is focal necrosis with macrophages
in association with diﬀuse reactive gliosis and microglial
activation [3, 7], and it is possible that diﬀerent mechanisms
areoperativeinproducingpre-OLdamageand focalnecrosis
as opposed to diﬀuse pre-OL damage without focal necrosis,
as seen in certain animal models (e.g., [81]). Given that
microglial activation is a hallmark of PVL, the role of
microglia relative to pre-OL injury is of critical interest.
The demonstration that the drug minocycline suppresses
microglial activation and substantially attenuates pre-OL
injury in perinatal rodent models of hypoxia ischemia is
important[83,84].Itunderscorestheroleofmicrogliainthe
pathogenesis of PVL, as suggested by focal macrophagocytic
inﬁltration and diﬀuse microglial activation in surrounding
nonnecrotic white matter [64], and provides a potential
eﬀective means of intervention [83, 84]. Microglia mediate
pre-OL cell death, at least in part, via pathways of oxidative
and nitrative stress [84].
Indeed, it is likely that macro- and microcysts in the
whitematterresultwhentheischemicinsultissevereenough
to cause concomitant gray matter injury, as suggested by
the ﬁnding that gray matter neuronal loss and/or gliosis
in the human preterm infant occurs only in association
with necrotic foci and not with gliosis alone [9] and that
prolonged ischemia in the sheep model results in white and
gray matter pathology [98]. In the past, animal models have
been sought that demonstrate white matter injury exclu-
sively, and those with both gray and white matter injury were
considered undesirable. It is likely, however, that in the eﬀort
to “create” only white matter injury (without associated gray
matter injury), that is, the historically perceived dominant
pathology of the preterm infant [4], animal models were
based upon lesser degrees of insult that “stopped short”
of (white or gray matter) necrosis, and the insult was not
severe enough to recapitulate the entire spectrum of the
human pathology. The challenge in animal modeling now
is to discover the timing, degree, and type of insult that
recapitulate the full human spectrum if further advances, in
our opinion, are to be made.
The approach to modeling the whole spectrum of EP
is indeed complicated, and may not be possible, given
the complexity of the histopathology, the nonspeciﬁcity of
certain lesions, for example, neuronal loss and gliosis, the
likelihood that multiple insults are involved, for example,
ischemia, infection, hemorrhage, hyperbilirubinemia, and
hypoglycemia, and the variable timing (e.g., intermittent,
recurrent) and intensity of the insults. The analysis of
the thalamus in association with PVL indicates heteroge-
neouslesionsimplicatingdiﬀerentmechanisms,forexample,
diﬀuse gliosis and neuronal loss consistent with general-
ized hypoxia ischemia, microinfarcts consistent with small
arterial vessel thrombi, and large infarcts consistent with
large (posterior arterial) occlusions [69]. The underde-
velopment of the cerebellum in the preterm infant may
not be directly related to hypoxia ischemia but rather to
a secondary consequence of intraventricular hemorrhage,
heme deposition in the leptomeninges, and heme toxicity
to the external granular layer with secondary cell loss and
impaired migration to the internal granular layer [72].
One approach to analyzing the whole spectrum of EP
is to focus upon animal models that mimic the circum-
stances of prematurity in the modern neonatal intensive
care nursery without a speciﬁc single severe insult. In
this regard, the baboon model of preterm delivery and
subsequent care with mechanical ventilation, blood gas
and electrolyte monitoring, and administration of pressors
indicates a spectrum of white matter injury, including
focal necrosis, gray matter (hippocampus) injury, focal and
leptomeningeal hemorrhages, and ventriculomegaly that in
multiple respects mirrors human EP [108]. This model
allows for the determination of the natural history of injury
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most closely reﬂect that of the human preterm infant.
While this baboon model does not provide the unequivocal
establishment of the speciﬁc mechanism of pre-OL cell
death, it allows for the determination of the sequence of pre-
OL cell injury in the setting of the multiple insults of human
prematurity and intensive management.
Animal models of EP need to focus upon combined
gray and white matter injury to facilitate the discovery of
shared cellular and molecular pathways that lead to pre-
OL, axonal, and neuronal damage that are all seen in
the single “snapshot” at tone time under the microscope,
having occurred simultaneously or at diﬀerent times in the
newborn’s clinical course. Developing neurons, axons, and
OLs, for example, are known to share molecular pathways
leading to apoptosis and thus the development of a drug that
targets these pathways could potentially prevent neuronal
and pre-OL cell death at the same time. Shared pathways
may relate also to glutamate receptors and free radical
defenses, as these factors involve both pre-OL and neuronal
toxicity [8]. Both cell types, for example, express glutamate
receptor subtypes in the human preterm brain that mediate
excitotoxicity[27–29],andanimalmodelsthattestglutamate
receptor antagonists need to assess protection of both white
and gray matter populations. Alternatively, drug testing in
animalmodelsmayneedtoprovideanagentthattargetspre-
OL injury and one that targets neuronal injury at the same
time. Indeed, combined models that delineate mechanistic
commonalities between pre-OLs, neurons, and axons may
yield synergistic therapeutic agents that prove to be the most
eﬀective in preventing the global consequences of EP. The
sheep model, for example, demonstrates white matter injury
in conjunction with basal ganglia and cortical injury [98],
and the elucidation of the mechanisms underlying these
combined lesions could indeed be sought in this key model.
4.6. Synergy between Human Neuropathologic and Animal
Models Studies in Translational Research in EP. Translational
research is advanced by the analysis of human and animal
studies in parallel, with each approach informing the other.
This vital synergy is well illustrated by the recent study
of the role of ceramide, a bioactive sphingolipid pivotal to
sphingolipid metabolism pathways, in PVL in which parallel
human and animal analyses were presented in a single com-
prehensive publication [114]. Ceramide, which regulates cell
deathinresponsetodiversestimuli,wasfoundtoaccumulate
in reactive astrocytes in the diﬀuse component of human
PVL by immunocytochemical methods, thereby establishing
it as a factor in the human pathology [114]. Next, ceramide
was reported in cell culture to interact with the cytokine
tumor necrosis factor, resulting in apoptotic death of OLs in
anastrocyte-dependentmanner.Finally,alteredsphingolipid
metabolism was restored during spontaneous remyelination
following toxic-induced demyelination in a whole animal
model.Takentogether,thesestudiessuggestthatthemodula-
tion of sphingolipid signaling pathways in reactive astrocytes
is a potentially important and novel means to prevent PVL
in humans [114]. The demonstration of ceramide accumula-
tion in reactive astrocytes in PVL solidiﬁed the relevance of
the experimental ﬁndings to the human condition. A second
example of the synergistic value of human, whole animal,
and cell culture models concerns the presence of GluR2
AMPA-deﬁcient receptors and NMDA receptors on pre-OLs
and the protection aﬀorded by respectively topiramate and
memantine against excitotoxicity [81, 82]. In addition, the
discovery of diﬀuse microglial activation in the white matter
surrounding necrotic foci led to a body of experimental
data demonstrating the role of microglia in innate immunity
in microglial activation, toll-like receptor biology, necrotic
reactions, cytokine production, and free radical generation
[8, 94, 115, 116], with the potential therapeutic relevance
of the amelioration by minocycline of white matter damage
in animal models [81, 82]. The synthesis of the human and
animal data leads in turn to the provocative insight that
microgliaarethecritical“convergencepoint”inthepotentia-
tionofhypoxicischemicandinfectious/inﬂammatoryinsults
in PVL, as recently reviewed in depth [8].
5. Conclusions
The pathology of EP is complex and heterogeneous and
mandates multiple types of large and small animal models
to address all of its many facets in global and cell-speciﬁc
paradigms. It could be argued that the “best” animal in
which to model EP is the animal in which EP occurs in the
natural state, as in the report of PVL in neonatal monkeys
born prematurely [117]: here all of the “right”, human-like,
factors must be in place, operative, and spontaneous. While
no one experimental model captures all of the complexity
of the human disorder, important advances in our under-
standing of preterm brain injury have resulted from diﬀerent
experimental approaches that focus on diﬀerent questions,
resulting in an increasingly complete picture. In tandem
with animal models are the human neuropathologic studies
with state-of-the-art methods, including gene expression
proﬁling [49], proteomics [118], western blotting [29, 30,
41, 44, 50, 52], stereology [119], array tomography [120],
immunoprecipitation and protein identiﬁcation [42], tissue
receptor autoradiography [27, 28, 50, 58, 59], single- and
double-label immunocytochemistry [22, 23, 29, 38, 64],
biochemical assays [65], histochemistry [30, 39], electron
microscopy [39, 40], and confocal microscopy [22], as well
as the ever-valuable Golgi technique [16, 40, 48, 75]. Yet, at
this time of unprecedented tools for human brain analysis,
the autopsy rates are unacceptably low. We urgently need to
develop a culture among those caring for premature infants
that place supreme value upon the role of the autopsy in
researchsothatfamiliesarereadilyandroutinelyapproached
for consent. Central tissue banks have also been advocated
to facilitate preterm brain research given the diﬃculties
for any one single investigator to accrue suﬃcient sample
sizes [96]. In addition, the scientiﬁc community at large
needs to place a premium on the unique role of human
neuropathologic studies in translational research, with an
appreciation of the applicability of highly sophisticated and
quantitative tools for tissue analysis for which the eﬀects
of postmortem can be corrected. Rather than downplayingNeurology Research International 13
human autopsy-based research as not “mechanism driven”
or “hypothesis testing”, the scientiﬁc community should
value such investigation for its many strengths, speciﬁcally
the role in deﬁning the major cell types, brain regions, and
molecules in the human condition and generating relevant
hypotheses for mechanistic testing in experimental systems.
In short, human and animal studies in parallel are essential
to inform and build upon each other; one without the other
just won’t work.
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